Who are Lorcaserin HCl's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): lorcaserin + phentermine-HCl, OPC-1085EL, JNT-517 Tablet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lorcaserin-hcl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Lorcaserin HCl — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lorcaserin HCl (Lorcaserin HCl) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-HT2C receptor agonist. Area: Obesity/Weight Management.

marketed 5-HT2C receptor agonist 5-HT2C receptor Obesity/Weight Management Small molecule Live · refreshed every 30 min

Target snapshot

Lorcaserin HCl (Lorcaserin HCl) — Beth Israel Deaconess Medical Center. Lorcaserin is a selective serotonin 5-HT2C receptor agonist that promotes weight loss by increasing satiety and reducing appetite.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Lorcaserin HCl TARGET	Lorcaserin HCl	Beth Israel Deaconess Medical Center	marketed	5-HT2C receptor agonist	5-HT2C receptor
lorcaserin + phentermine-HCl	lorcaserin + phentermine-HCl	Eisai Inc.	marketed	Combination weight-loss agent (5-HT2C agonist + sympathomimetic amine)	5-HT2C receptor (lorcaserin); norepinephrine release (phentermine)
OPC-1085EL	OPC-1085EL	Otsuka Beijing Research Institute	phase 3	5-HT2C receptor agonist	5-HT2C receptor
JNT-517 Tablet	JNT-517 Tablet	Otsuka Pharmaceutical Development & Commercialization, Inc.	phase 3	5-HT2C receptor agonist	5-HT2C receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-HT2C receptor agonist class)

Beth Israel Deaconess Medical Center · 1 drug in this class
Otsuka Beijing Research Institute · 1 drug in this class
Otsuka Pharmaceutical Development & Commercialization, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lorcaserin HCl — Competitive Intelligence Brief. https://druglandscape.com/ci/lorcaserin-hcl. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing